Stocks›Healthcare›NAMS

NAMS

NewAmsterdam Pharma Company N.V.

NasdaqResearch view

Healthcare · Pharmaceutical Preparations · Mid-cap · SEC EDGAR FY 2025-12-31

Price history

Chart: TradingView’s own feed · page prices: 1D EOD

🔒 Click to interact · scroll moves the page

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$2.7B

Enterprise Value$2.2B

Income$-203.0M

Sales$22.5M

Book/sh$5.72

Cash/sh$4.10

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio7.88

Debt/Eq—

EPS (ttm)$-1.72

EPS this Y32.8%

EPS past 3/5Y—

Sales past 3/5Y-39.7%

EPS Y/Y TTM32.8%

Sales Y/Y TTM-50.6%

Shs Outstand119.54M

ROA-26.4%

ROE-29.7%

ROIC-116.7%

Gross Margin—

Oper. Margin-1002.9%

Profit Margin-902.1%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue & Earnings — fiscal year

$102.7M

2022

$14.1M

2023

$45.6M

2024

$22.5M

2025

Financials — annual

SEC EDGAR · last 4 FY · tap a row to explain it

USD	FY2022	FY2023	FY2024	FY2025
Revenue	$102.7M	$14.1M	$45.6M	$22.5M
Gross Profit	—	—	—	—
Operating Income	$-3.6M	$-183.0M	$-176.3M	$-225.7M
Net Income	$-22.6M	$-177.0M	$-242.0M	$-203.0M
Diluted EPS	$-1.19	$-2.15	$-2.56	$-1.72
Operating Cash Flow	$10.7M	$-141.2M	$-158.6M	$-147.8M
Free Cash Flow	—	—	—	—

Deep dive

Computed from the SEC EDGAR multi-year statements

Operating leverage — margins

GrossOperatingNet

FY25 cash-flow waterfall

Cash-flow detail unavailable in this filing.

—

Follow the news. Track the move.

NAMS story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Regulation

Sep 21

Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

The European Commission approved obicetrapib products from Menarini Group and NewAmsterdam Pharma, marking the drug’s first global regulatory approval. The decision creates a commercial launch setup for NewAmsterdam while putting execution against the Phase 3 efficacy and tolerability profile into focus.

Price history unavailable

PR Newswire · 1h ago

View both sides →

Follow the news. Track the move.